BACKGROUND:Chronic obstructive pulmonary disease (COPD) treatment goals are often not achieved despite the availability of many effective treatments. Furthermore, clinical pharmacist interventions to improve clinical and humanistic outcomes in COPD patients have not yet been explored and few randomized controlled trials have been reported to evaluate the impact of pharmaceutical care on health outcomes in patients with COPD. OBJECTIVE: The aim of the present study was to evaluate the impact of pharmaceutical care intervention, with a strong focus on self-management, on a range of clinical and humanistic outcomes in patients with COPD. SETTING:Outpatient COPD Clinic at the Royal Medical Services Hospital. METHOD: In a randomised, controlled, prospective clinical trial, a total of 133 COPD patients were randomly assigned to intervention or control group. A structured education about COPD and management of its symptoms was delivered by the clinical pharmacist for patients in the intervention group. Patients were followed up at 6 months during a scheduled visit. Effectiveness of the intervention was assessed in terms of improvement in health-related quality of life, medication adherence, disease knowledge and healthcare utilization. Data collected at baseline and at the 6 month assessment was coded and entered into SPSS(®) software version 17 for statistical analysis. A P value of <0.05 was considered statistically significant. MAIN OUTCOME MEASURE: The primary outcome measure was health-related quality of life improvement. All other data collected including healthcare utilization, COPD knowledge and medication adherence formed secondary outcome measures. RESULTS: A total of 66 patients were randomized to the intervention group and 67 patients were randomized to the control group. Although the current study failed to illustrate significant improvement in health-related quality of life parameters, the results indicated significant improvements in COPD knowledge (P < 0.001), medication adherence (P < 0.05), medication beliefs (P < 0.01) and significant reduction in hospital admission rates (P < 0.05) in intervention patients when compared with control group patients at the end of the study. CONCLUSION: The enhanced patient outcomes as a result of the pharmaceutical care programme in the present study demonstrate the value of an enhanced clinical pharmacy service in achieving the desired health outcomes for patients with COPD.
RCT Entities:
BACKGROUND:Chronic obstructive pulmonary disease (COPD) treatment goals are often not achieved despite the availability of many effective treatments. Furthermore, clinical pharmacist interventions to improve clinical and humanistic outcomes in COPDpatients have not yet been explored and few randomized controlled trials have been reported to evaluate the impact of pharmaceutical care on health outcomes in patients with COPD. OBJECTIVE: The aim of the present study was to evaluate the impact of pharmaceutical care intervention, with a strong focus on self-management, on a range of clinical and humanistic outcomes in patients with COPD. SETTING:OutpatientCOPD Clinic at the Royal Medical Services Hospital. METHOD: In a randomised, controlled, prospective clinical trial, a total of 133 COPDpatients were randomly assigned to intervention or control group. A structured education about COPD and management of its symptoms was delivered by the clinical pharmacist for patients in the intervention group. Patients were followed up at 6 months during a scheduled visit. Effectiveness of the intervention was assessed in terms of improvement in health-related quality of life, medication adherence, disease knowledge and healthcare utilization. Data collected at baseline and at the 6 month assessment was coded and entered into SPSS(®) software version 17 for statistical analysis. A P value of <0.05 was considered statistically significant. MAIN OUTCOME MEASURE: The primary outcome measure was health-related quality of life improvement. All other data collected including healthcare utilization, COPD knowledge and medication adherence formed secondary outcome measures. RESULTS: A total of 66 patients were randomized to the intervention group and 67 patients were randomized to the control group. Although the current study failed to illustrate significant improvement in health-related quality of life parameters, the results indicated significant improvements in COPD knowledge (P < 0.001), medication adherence (P < 0.05), medication beliefs (P < 0.01) and significant reduction in hospital admission rates (P < 0.05) in intervention patients when compared with control group patients at the end of the study. CONCLUSION: The enhanced patient outcomes as a result of the pharmaceutical care programme in the present study demonstrate the value of an enhanced clinical pharmacy service in achieving the desired health outcomes for patients with COPD.
Authors: Lotte Steuten; Bert Vrijhoef; Frits Van Merode; Geert-Jan Wesseling; Cor Spreeuwenberg Journal: Int J Qual Health Care Date: 2006-10-10 Impact factor: 2.038
Authors: A Casas; T Troosters; J Garcia-Aymerich; J Roca; C Hernández; A Alonso; F del Pozo; P de Toledo; J M Antó; R Rodríguez-Roisín; M Decramer Journal: Eur Respir J Date: 2006-04-12 Impact factor: 16.671
Authors: J Bourbeau; R J Sebaldt; A Day; J Bouchard; A Kaplan; P Hernandez; M Rouleau; A Petrie; G Foster; L Thabane; J Haddon; A Scalera Journal: Can Respir J Date: 2008 Jan-Feb Impact factor: 2.409
Authors: Anke Lenferink; Marjolein Brusse-Keizer; Paul Dlpm van der Valk; Peter A Frith; Marlies Zwerink; Evelyn M Monninkhof; Job van der Palen; Tanja W Effing Journal: Cochrane Database Syst Rev Date: 2017-08-04
Authors: Kirla B Detoni; Isabela V Oliveira; Mariana M G Nascimento; Thaís R Caux; Mateus R Alves; Djenane Ramalho-de-Oliveira Journal: Int J Clin Pharm Date: 2016-12-03
Authors: Eline Tommelein; Els Mehuys; Thierry Van Hees; Els Adriaens; Luc Van Bortel; Thierry Christiaens; Inge Van Tongelen; Jean-Paul Remon; Koen Boussery; Guy Brusselle Journal: Br J Clin Pharmacol Date: 2014-05 Impact factor: 4.335
Authors: Stefan Ottenbros; Martina Teichert; Romy de Groot; Fabienne Griens; Fong Sodihardjo; Michel Wensing; J J de Gier Journal: Int J Clin Pharm Date: 2013-12-01